Abstract:Background: Immune checkpoint inhibitors (ICIs) are a class of immunotherapy that enhance a patient's anti-cancer immune response, but only a small percentage of patients who are treated respond. This means patients who do not respond undergo costly and side effect-inducing treatment for no benefit indicating a need for improved selection criteria. Current predictive biomarkers include immunohistochemical (IHC) detection of PD-L1 but are insufficient for determining who will respond or, more importantly in the adjuvant setting, who will not respond. Methods: This study utilizes a research use only (RUO*) quantitative real-time reverse transcription polymerase chain reaction assay, the GeneXpert® (GX) PD-L1 panel prototype assay, to test for the association between 4 target immune genes, CD274 (PD-L1), PDCD1LG2 (PD-L2), CD8A, and IRF1, and response to ICI therapy. Tissues were collected from 122 patients with advanced non-small cell lung cancer prior to ICI therapy in a retrospective cohort, macro-dissected, and analyzed using the PD-L1 prototype assay. Lysates were run on the GX instrument using the PD-L1 prototype assay. Individual transcripts were quantitated for each sample and the association with response was assessed. Median mRNA expression was used as a cutpoint to look at survival, clinical response and positive and negative predictive value (PPV, NPV). Optimal cutpoint was determined using Rstudio to also assess PPV and NPV. This study was approved by Yale Human Investigation IRB protocol ID 9505008219. Results: Both high PD-L1 and PD-L2 mRNA, defined by median, were associated with improved long-term benefit at 24-months (PD-L1, p=0.0416; PD-L2, p=0.0435) and overall survival (PD-L1, p=0.047; PD-L2, p=0.047). Furthermore, low PD-L1 mRNA, defined by optimal cutpoint, showed a negative predictive value of 0.92. Conclusions: High PD-L1 and PD-L2 mRNA, measured by GX, are associated with improved long-term benefit and overall survival. Importantly, low PD-L1 mRNA has a high negative predictive value. Given the simplicity and reproducibility of the GX system, with further validation this assay could be an improved method for selecting patients for treatment in the advanced setting, or more importantly, to determine which low stage patients should not be treated in the adjuvant setting. *For research use only. Not for use in diagnostic procedures. Citation Format: Aileen I. Fernandez, Niki Gavrielatou, Leena McCann, Saba Shafi, Myrto K. Moutafi, Sandra Martinez-Morilla, Ioannis Vathiotis, Thazin Nwe Aung, Vesal Yaghoobi, Yalai Bai, Jodi Weidler, Michael Bates, David L. Rimm. PD-L1 and PD-L2 mRNA are associated with outcome and high negative predictive value in immunotherapy-treated non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 1242.

PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer

Development of Nomograms to Predict Therapeutic Response and Prognosis of Non-Small Cell Lung Cancer Patients Treated with Anti-Pd-1 Antibody

Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

Clinical Significance and Molecular Annotation for PD-L1 Negative Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Dual PD-1/CTLA-4 Blockade

PD-1 expression in tumor infiltrating lymphocytes as a prognostic marker in early-stage non-small cell lung cancer

Predictive value of the biomarker of peripheral blood of NSCLC patients responding to anti-PD-1 treatment

Abstract 1242: PD-L1 and PD-L2 mRNA are associated with outcome and high negative predictive value in immunotherapy-treated non-small cell lung cancer

Potential Role of Circulating PD-L1+ Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients

Intratumoral CD39+CD8+ T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC

Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer

PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study

Association of PD-L 1 expression with clinicopathologic features and overall survival in patients with non-small-cell lung cancer

Longitudinal High-Dimensional Analysis Identifies Biomarkers of Response to Anti-PD-1 Immunotherapy

Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials

Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer

PD-L1 Expression and Comprehensive Molecular Profiling Predict Survival in Nonsmall Cell Lung Cancer: A Real-World Study of a Large Chinese Cohort

The Association of PD-L1 Expression with the Efficacy of Anti-Pd-1/pd-l1 Immunotherapy and Survival of Non-Small Cell Lung Cancer Patients: a Meta-Analysis of Randomized Controlled Trials

Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC